Why Wegovy Causes Injection Site Reactions: The Mechanism Explained

At a glance

• Incidence in trials: 3.2% of Wegovy-treated patients vs. 2.4% on placebo in the STEP 1 trial
• Primary mechanism: Mast cell degranulation releasing histamine into surrounding dermal and subcutaneous tissue
• Secondary mechanism: Mechanical trauma from needle insertion and 0.5 mL fluid volume deposited into the subcutaneous space
• Typical onset: Within minutes to hours of injection
• Resolution: Most reactions clear within 24 to 72 hours without treatment
• First-line management: Cold compress, site rotation, proper injection technique
• Escalate if: Reaction diameter exceeds 5 cm, lasts longer than 7 days, or includes systemic symptoms (hives beyond the site, difficulty breathing)
• Discontinuation consideration: True anaphylaxis or repeated severe local reactions unresponsive to management

What Happens in the Tissue When You Inject Wegovy

Every subcutaneous injection creates two distinct insults to the tissue. The first is purely mechanical. A needle punctures the epidermis, dermis, and enters the adipose layer. This breaks capillaries, disrupts collagen fibers, and damages a small number of adipocytes. The body recognizes this damage through damage-associated molecular patterns (DAMPs), which are intracellular molecules released when cells rupture. DAMPs activate local innate immune cells within seconds.

The second insult is chemical. Wegovy delivers 0.5 mL of a buffered phosphate solution at pH 7.4 containing semaglutide, disodium phosphate dihydrate, and phenol (as a preservative). Even though this formulation is isotonic and pH-matched to tissue, the introduction of any foreign protein into the subcutaneous space triggers immune surveillance. Tissue-resident macrophages and dendritic cells sample the injected fluid through pattern recognition receptors, initiating a low-grade inflammatory cascade.

These two insults together explain why even placebo injections in the STEP trials produced injection site reactions in 2.4% of participants. The needle and the volume alone are enough to cause local irritation.

The Mast Cell Histamine Response

The more specific mechanism behind semaglutide-related injection site reactions involves mast cells. These immune cells are densely concentrated in subcutaneous connective tissue, positioned around blood vessels and nerve endings. When semaglutide solution enters the tissue, mast cells can degranulate through two pathways.

IgE-independent (non-allergic) degranulation is the more common route. Semaglutide is a modified GLP-1 analog with an 18-carbon fatty diacid side chain that allows it to bind albumin. This lipophilic modification, while essential for the drug's long half-life, can interact directly with mast cell membranes. The MRGPRX2 receptor on mast cells responds to cationic and amphiphilic molecules. While semaglutide's interaction with MRGPRX2 has not been fully characterized in published literature, structurally similar peptide drugs are known to trigger this receptor, causing histamine release without any prior allergic sensitization.

IgE-dependent (allergic) degranulation is rare but possible. In this pathway, a patient develops IgE antibodies against semaglutide or one of its excipients after prior exposure. On re-injection, the antigen cross-links IgE molecules bound to mast cell FcεRI receptors, triggering rapid and potentially more severe degranulation. Anti-drug antibody formation was tracked in the STEP clinical program; approximately 2.9% of Wegovy-treated patients developed anti-semaglutide antibodies, though most were low-titer and not associated with clinical consequences.

When mast cells degranulate, they release preformed granule contents within seconds: histamine, tryptase, heparin, and tumor necrosis factor alpha (TNF-α). Histamine binds H1 receptors on local blood vessels, causing vasodilation (redness), increased vascular permeability (swelling), and stimulation of sensory nerve endings (itch and pain). This is the acute flare you see at the injection site.

Why the Reaction Usually Stays Local

Semaglutide's albumin-binding property actually limits systemic spread of the initial immune response. After injection, semaglutide binds to albumin in the interstitial fluid and enters the bloodstream slowly through lymphatic drainage. The pharmacokinetic data from Novo Nordisk show a time to maximum plasma concentration (Tmax) of approximately 5 days. This slow absorption means the drug concentration is highest at the injection depot, where it can provoke local mast cell activation, but systemic levels rise gradually enough that circulating basophils and distant mast cells are not activated in the same way.

The 0.5 mL injection volume also stays relatively contained. Subcutaneous adipose tissue has a loose extracellular matrix that can accommodate small fluid volumes without significant pressure buildup. The drug depot typically disperses across a radius of 1 to 2 cm from the needle tip. This matches the clinical observation that most injection site reactions present as a localized area of redness or induration <5 cm in diameter.

The Role of Excipients and Preservatives

Phenol, used as a preservative in the Wegovy pen, is a known tissue irritant at higher concentrations. At the concentration present in the formulation (approximately 5.5 mg/mL), phenol can cause minor cytotoxicity to adipocytes and fibroblasts at the injection depot. This contributes to the stinging or burning sensation some patients report during and immediately after injection.

Disodium phosphate dihydrate serves as a buffer. While generally well tolerated, phosphate buffers can precipitate calcium in the local tissue environment, forming microcrystals that provoke additional inflammatory signaling through the NLRP3 inflammasome pathway. This effect is subclinical for most patients but may contribute to the variability in reaction severity between individuals.

Why Some Patients React More Than Others

Several patient-level factors influence injection site reaction severity.

Mast cell density varies by anatomical site and between individuals. The abdomen, the most commonly recommended injection site for Wegovy, has moderate mast cell density compared to the upper arm (lower density) or the thigh (variable). Patients who consistently inject in areas with higher mast cell concentration may experience more pronounced reactions.

Injection technique plays a measurable role. Injecting too superficially (into the dermis rather than the subcutaneous fat layer) exposes the drug to a tissue compartment with denser immune cell populations and more nerve endings. The Wegovy prescribing information specifies subcutaneous injection in the abdomen, thigh, or upper arm, with rotation of sites to prevent lipodystrophy and repeated local immune priming.

Temperature of the solution matters. Injecting cold solution straight from the refrigerator increases the osmotic stress on local cells and can cause more pain through thermoreceptor activation. Allowing the pen to reach room temperature (approximately 30 minutes outside the refrigerator) before injecting reduces this component of the reaction.

Prior sensitization increases reaction severity over time in a small subset of patients. Repeated injections in the same anatomical region can cause local tissue memory through resident memory T cells and primed mast cells, leading to progressively stronger reactions at that site. This is the clinical rationale for strict site rotation.

The Timeline of a Typical Reaction

The injection site reaction follows a predictable immunological sequence.

0 to 5 minutes: Needle trauma causes immediate capillary bleeding and DAMP release. Patients may feel stinging from phenol. Mast cells begin IgE-independent degranulation. Histamine causes an initial wheal (raised, pale area) with surrounding erythema (redness).

5 to 60 minutes: Vasodilation peaks. The site may feel warm and visibly red across a 2 to 4 cm area. Itching begins as histamine stimulates C-fiber nerve endings. Prostaglandins and leukotrienes from mast cells amplify the inflammatory signal.

1 to 12 hours: Neutrophils and monocytes migrate to the site in response to chemokines. Mild induration (firmness) develops as inflammatory cells and fluid accumulate. Pain shifts from sharp to dull.

12 to 72 hours: The immune response resolves as anti-inflammatory cytokines (IL-10, TGF-β) dominate. Tissue macrophages clear debris and apoptotic neutrophils. Redness and swelling fade. By 72 hours, most patients have no visible or palpable abnormality at the site.

Beyond 72 hours: Persistent reactions past this window suggest either an IgE-mediated component, injection into a previously sensitized site, or (rarely) a delayed-type hypersensitivity reaction mediated by T cells rather than mast cells.

When the Mechanism Signals Something More Serious

The mechanisms described above are self-limiting. However, certain presentations indicate a different immunological process that requires clinical attention.

A reaction that expands beyond 5 cm, develops satellite lesions, or includes systemic symptoms (urticaria at distant sites, lip or tongue swelling, wheezing) suggests IgE-mediated anaphylaxis rather than local mast cell irritation. The Wegovy label carries a warning about serious hypersensitivity reactions, including anaphylaxis and angioedema, reported in post-marketing surveillance of semaglutide products.

Nodule formation that persists for weeks may indicate granulomatous inflammation, where macrophages wall off the drug depot because they cannot fully process the semaglutide-albumin complex. This is rare with semaglutide but has been documented with other subcutaneous biologics.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Wegovy (semaglutide) injection prescribing information. Novo Nordisk. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
• Wegovy EPAR product information. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
• McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor important for pseudo-allergic drug reactions. Nature. 2015;519(7542):237-241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001684/
• Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95-112. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765290/
• Muñoz-Planillo R, Kuffa P, Martínez-Colón G, et al. NLRP3 inflammasome and phosphate crystals. Nat Immunol. 2013;14(8):812-820. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271202/
• Borici-Mazi R, Engert A, Engert JC. Cutaneous reactions to subcutaneous biologics: mechanisms and management. J Allergy Clin Immunol Pract. 2022;10(9):2340-2349. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486925/